MedTech Dive · Aug 6, 2026
Zimmer Biomet sales force revamp going better than expected, CEO says
The restructuring, intended to give Zimmer Biomet a fully dedicated sales force, is expected to be complete by the end of 2027.
Medical Technology
Devices, digital health, and the technology changing how care is delivered.
MedCity News · Aug 6, 2026
Connecting the Dots: How Oral Health Can Enable Whole-Person Care
The industry has made real progress in recognizing that oral health belongs at the center of whole-person care, but intent alone isn’t enough. To translate this vision into something tangible, the industry must invest in infrastructure that makes integration not only possible but scalable. The post Connecting the Dots: How Oral Health Can Enable Whole-Person Care appeared first on MedCity News .
MedCity News · Aug 6, 2026
Should You Centralize Cold Chain Fulfillment? Only If You’ve Solved Distribution First
Cold chain is a logistics problem — not just a throughput problem. Pharmacies must rethink their strategy, not just automate it. The post Should You Centralize Cold Chain Fulfillment? Only If You’ve Solved Distribution First appeared first on MedCity News .
Fierce Biotech · Aug 6, 2026
Double shot of Vistagen’s anxiety nasal spray can’t beat placebo in ph. 2 trial
Following a string of clinical setbacks, Vistagen’s nasal spray for social anxiety has now failed to top placebo even when given as a double dose. But just like with prior disappointing readouts, the biotech has set its sights on a subpopulation it says may provide a path to FDA approval.
Fierce Biotech · Aug 6, 2026
PacBio CEO steps down as Q2 loss widens
PacBio has promoted an internal veteran to CEO after Christian Henry stepped down, tasking the new leader with improving sales, expanding the DNA sequencing company’s clinical reach and cutting costs.
Fierce Biotech · Aug 6, 2026
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.
Fierce Biotech · Aug 6, 2026
Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday
Actimed Therapeutics has brought the full rights to its wasting disease drug back in-house, securing “strategic control” over the asset but losing out on a shot at over $120 million in biobucks.
Fierce Biotech · Aug 6, 2026
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.
MedCity News · Aug 5, 2026
6 Ways UnityPoint Health Is Trying to Make Clinicians’ Jobs Easier
UnityPoint Health’s chief medical officer, Gregory Johnson, shared several ways the system is using AI to lift administrative burden off clinicians and get them back to patient care — including ambient scribing, real-time capacity tracking and AI-powered chart review. The post 6 Ways UnityPoint Health Is Trying to Make Clinicians’ Jobs Easier appeared first on MedCity News .
MedCity News · Aug 5, 2026
Curative, Wondr Health Team Up for Weight and Metabolic Health Support
Curative Insurance Company partnered with Wondr Health to expand weight management support for its members. The post Curative, Wondr Health Team Up for Weight and Metabolic Health Support appeared first on MedCity News .
MedTech Dive · Aug 5, 2026
Medtronic on the future of AI-assisted surgery
Medtronic’s George Murgatroyd says an advanced computing platform that works with the company’s Hugo robot will power AI algorithms that can assist surgeons as they operate.
MedCity News · Aug 5, 2026
Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders
Attovia Therapeutics’ biologic medicines could offer advantages over currently available immune disorder drugs, such as Sanofi’s blockbuster medicine Dupixent. The IPO comes as Attovia looks to expand clinical development of its pipeline in 2027. The post Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders appeared first on MedCity News .
Fierce Biotech · Aug 5, 2026
Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring
Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”
ADA (Diabetes) · Aug 5, 2026
The American Diabetes Association Applauds Hawai’i’s Enactment of SB 3045, Expanding Access to Continuous Glucose Monitors
The American Diabetes Association Applauds Hawai’i’s Enactment of SB 3045, Expanding Access to Continuous Glucose Monitors mcarmody Wed, 08/05/2026 - 17:47 Advocacy News The American Diabetes Association Applauds Hawai’i’s Enactment of SB 3045, Expanding Access to Continuous Glucose Monitors HONOLULU, Hawaii August 5, 2026 The American Diabetes Association ® (ADA) applauds Hawaii Governor Josh Green for signing SB 3045 into law, a significant step toward expanding access to continuous glucose monitors (CGMs) for people living with diabetes across Hawaiʻi. The new law requires health…
Fierce Biotech · Aug 5, 2026
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking off the cobwebs thanks in part to substantial investments from billionaires Bill Gates and Jeff Bezos.
MedTech Dive · Aug 5, 2026
STAAR Surgical appoints Warren Foust as permanent CEO
The implantable eye lens company began searching for a new CEO shortly after its sale to Alcon collapsed in January.
MedCity News · Aug 5, 2026
The Sleep Crisis We May Be Missing: Why Millions of Americans Remain Undiagnosed
Despite the silk masks, oils, and sleepy girl mocktails swirling around social media, one of the greatest causes of non-restorative sleep is rarely mentioned by wellness influencers online: actual sleep disorders. The post The Sleep Crisis We May Be Missing: Why Millions of Americans Remain Undiagnosed appeared first on MedCity News .
MedCity News · Aug 5, 2026
The Healthcare Leaders Driving Change Need to Get Better at Explaining It
Healthcare leaders who shape that future need more than innovation. They need a visible, credible voice that helps the people around them — patients, clinicians, employees, partners, and investors — understand what the change is, why it matters, and why this is the right person to lead it. The post The Healthcare Leaders Driving Change Need to Get Better at Explaining It appeared first on MedCity News .
Fierce Biotech · Aug 5, 2026
Fecal transplant increases tolerance to peanuts sixfold in small food allergy trial
Fecal transplants can increase tolerance to peanuts sixfold in people with food allergies, new research out of Boston Children’s Hospital has suggested.
Fierce Biotech · Aug 5, 2026
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
Novo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is already on the hunt for bolt-on deals.
Fierce Biotech · Aug 5, 2026
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
Attovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a banner year for biotech Nasdaq debuts.
MedCity News · Aug 4, 2026
How Policymakers Can Improve Obesity Treatment and Affordability, Per American College of Physicians
The American College of Physicians is urging policymakers to expand access to obesity treatment and healthy foods while investing in prevention and research. The post How Policymakers Can Improve Obesity Treatment and Affordability, Per American College of Physicians appeared first on MedCity News .
MedCity News · Aug 4, 2026
Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents
Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company’s cancer drug pipeline. The post Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents appeared first on MedCity News .
MedTech Dive · Aug 4, 2026
Caristo wins FDA authorization for cardiovascular risk predictor
The University of Oxford spinout will soon launch the AI tool, which research suggests could help assess heart attack risk in patients who don’t have obstructive coronary artery disease.